A report published this morning by the Canadian health authority has confirmed that a generic version of the blockbuster diabetes drug Ozempic will be available in Canada at a fraction of the price charged in the United States. The development underscores the structural inefficiencies of the American pharmaceutical market and lends credence to critics who argue that the UK’s National Health Service model offers a more rational approach to drug pricing.
The Canadian generic, produced by a domestic manufacturer under licence, will retail at approximately $150 per month. In the United States, the branded version of Ozempic, produced by Novo Nordisk, costs patients upwards of $900 per month without insurance. The disparity is not an anomaly but a feature of a system that lacks centralised price negotiation. The US government is statutorily barred from negotiating drug prices for Medicare, a restriction that has long been criticised by health economists.
Canada, like the United Kingdom, employs a single-payer framework for many of its healthcare costs. The Patented Medicine Prices Review Board, a federal agency, sets maximum prices for patented drugs based on a basket of comparable countries. The United Kingdom’s National Institute for Health and Care Excellence goes further, assessing both clinical effectiveness and cost-effectiveness before approving NHS coverage. The result is that the NHS pays roughly a quarter of what US insurers pay for the same drugs.
The generic Ozempic in Canada is not a regulatory aberration. It is the product of a deliberate policy to increase access to essential medicines. Health Canada fast-tracked approval after the manufacturer demonstrated bioequivalence. The move has been welcomed by patient advocacy groups, who note that diabetes affects nearly 4 million Canadians, many of whom struggle with medication costs.
The American pricing problem is not confined to Ozempic. A 2021 study in the Journal of the American Medical Association found that US prices for prescription drugs were 2.5 times higher than those in other high-income countries. The Inflation Reduction Act of 2022 introduced limited negotiation for a subset of drugs, but the most expensive classes near the top of the market remain untouched. The Canadian generics strategy bypasses this entirely by enabling competition before patents expire.
The British model, meanwhile, has enjoyed a quiet vindication. The NHS has secured deep discounts on Ozempic through bulk purchasing and its ability to walk away from unfavourable deals. Novo Nordisk has not been granted the same market power in the UK as it enjoys in the US, where direct-to-consumer advertising and physician incentive programmes drive demand. The Canadian announcement will be cited by advocates of NHS-style pricing in the ongoing US congressional hearings on drug costs.
Critics of the UK system point to slower access to new drugs and the potential for rationing. Yet the evidence suggests that the trade-off is accepted by the public. A 2023 poll found that 72 per cent of Britons trust the NHS to make value-based decisions about medicines. The Canadian case reinforces the viability of that approach.
For American patients, the news from Canada is a stark reminder of what is possible when governments prioritise public health over corporate profits. Senator Bernie Sanders, who has long campaigned for drug price reform, described the Canadian development as a direct indictment of the US system. He called for legislation to permit Medicare to negotiate prices and to allow importation of cheaper drugs from Canada and the UK.
Novo Nordisk has not commented on the Canadian generic’s pricing. The company continues to defend its US pricing as necessary to fund research and development. However, the company’s annual reports show that its profit margins are significantly higher in the US than in any other market. The Canadian generic is unlikely to affect Novo Nordisk’s bottom line in the near term, but it carries symbolic weight.
The broader lesson, according to health policy analysts, is that the free market has failed to deliver affordable medicines. The Canadian move is a stop gap, not a solution. Ultimately, the US must decide whether to adopt elements of the UK’s NHS model or accept permanent price disparities that leave millions of patients exposed.
